Anti‐viral therapy is associated with improved survival but is underutilised in patients with hepatitis B virus‐related hepatocellular carcinoma: real‐world east and west experience

Abstract

Anti-viral therapy improved overall survival in patients with HBV-related HCC across cancer stages and treatment types but was underutilised at both US and Asia centres. Expanded use of anti-viral therapy in HBV-related HCC and better linkage-to-care for HBV patients are needed.